Publications by authors named "M H Pillinger"
Article Synopsis
- - The study investigates the carbon monoxide (CO) releasing ability of the complex [CpMo(CO)Me] (1), demonstrating that sodium dithionite promotes CO release, especially when exposed to UV light, establishing it as a photochemically activated CO-releasing molecule.
- - Different methods, including liquid-liquid interfacial precipitation and mechanochemical ball-milling, were used to create inclusion complexes of 1 with β-cyclodextrin (βCD) and cucurbit[7]uril (CB7), resulting in confirmed inclusion compounds through various analytical techniques.
- - The inclusion of 1 with βCD or CB7 slowed down CO release rates compared to the non-included form, with β
Registration URL: https://clinicaltrials.gov. Unique identifier: NCT02594111.
View Article and Find Full Text PDFIntroduction: Patients with chronic refractory gout face a considerable burden of disease due to unexpected flares characterized by severe and debilitating pain, which can lead to chronic pain and joint damage. This study aimed to understand the symptoms and impacts of chronic refractory gout on health-related quality of life (HRQoL).
Methods: A targeted literature review was conducted to identify and review key articles describing the symptoms and impacts of gout, and articles examining the psychometric performance of the Medical Outcomes Survey Short Form-36 (SF-36) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in gout.
Over the past two decades, following the discovery of the important biological roles of carbon monoxide (CO), metal carbonyl complexes have been intensively studied as CO-releasing molecules (CORMs) for therapeutic applications. To improve the properties of "bare" low molecular weight CORMs, attention has been drawn to conjugating CORMs with macromolecular and inorganic scaffolds to produce CO-releasing materials (CORMAs) capable of storing and delivering large payloads of the gasotransmitter. A significant obstacle is to obtain CORMAs that retain the beneficial features of the parent CORMs.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the risk of arthritis flares when starting urate-lowering therapy (ULT) with allopurinol versus febuxostat in gout patients, focusing on the first 24 weeks of treatment.
- It analyzed data from a trial involving 940 male participants, examining flare occurrences and various predictors such as treatment type and serum urate levels.
- The findings indicated that the risk of gout flares was similar for both medications when using effective treatment strategies, with notable predictors of flare being younger age, higher initial urate levels, and the absence of tophi.